Comprehensive Stock Comparison
Compare CDT Equity Inc. (CDT) vs XOMA Corporation (XOMAP) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Stability / Safety |  XOMAP | Beta 0.13 vs CDT's 0.34 |
| Dividends | XOMAP | 1.8% yield; CDT pays no meaningful dividend |
| Momentum (1Y) | XOMAP | +8.7% vs CDT's -99.4% |
| Efficiency (ROA) | XOMAP | 8.3% ROA vs CDT's -237.4% |
Who Each Stock Is For
Income & stability
XOMAPDividend streak 0 yrs, beta 0.13, yield 1.8%
Growth exposure
XOMAPRev growth 498.7%, EPS growth 59.2%, 3Y rev CAGR -9.3%
Long-term compounding (10Y)
XOMAP50.5% 10Y total return vs CDT's -100.0%
Sleep-well-at-night portfolio
XOMAPLower volatility, beta 0.13, current ratio 5.15x
Defensive / Recession hedge
XOMAPBeta 0.13, yield 1.8%, current ratio 5.15x
Business Model
What each company does and how it makes money
CDT Equity is a healthcare company that facilitates the development and commercialization of clinical-stage medical assets. It generates revenue through licensing agreements, milestone payments, and equity stakes in the biotech companies it partners with — typically taking a share of future commercial success. Its key advantage lies in its founders' deep pharmaceutical industry expertise and strategic approach to identifying promising clinical assets with commercial potential.
XOMA Corporation is a biotechnology royalty aggregator that acquires future economic rights to pre-commercial therapeutic candidates licensed to pharmaceutical partners. It generates revenue primarily through milestone payments and royalties from its portfolio of approximately 70 early to mid-stage clinical assets — with no single asset dominating its income stream. The company's moat lies in its specialized expertise in evaluating and structuring royalty agreements for complex biotech assets, creating a diversified portfolio of potential future revenue streams.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
XOMAP 4
CDT 1CDT1/1 metricsXOMAP1/1 metricsXOMAP4/6 metricsXOMAP6/6 metricsXOMAP2/2 metricsXOMAP leads in 4 of 6 categories (Valuation Metrics, Profitability & Efficiency). CDT leads in 1 (Financial Metrics).
Financial Metrics (TTM)
XOMAP and CDT operate at a comparable scale, with $47M and $0 in trailing revenue.
| Metric | CDTCDT Equity Inc. | XOMAPXOMA Corporation |
|---|---|---|
| RevenueTrailing 12 months | $0 | $47M |
| EBITDAEarnings before interest/tax | -$17M | $13M |
| Net IncomeAfter-tax profit | -$20M | $22M |
| Free Cash FlowCash after capex | $34M | $5M |
| Gross MarginGross profit ÷ Revenue | — | +93.6% |
| Operating MarginEBIT ÷ Revenue | — | -15.0% |
| Net MarginNet income ÷ Revenue | — | +46.1% |
| FCF MarginFCF ÷ Revenue | — | +11.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +29.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +2.1% | +144.0% |
Valuation Metrics
| Metric | CDTCDT Equity Inc. | XOMAPXOMA Corporation |
|---|---|---|
| Market CapShares × price | $1M | $317M |
| Enterprise ValueMkt cap + debt − cash | $8M | $335M |
| Trailing P/EPrice ÷ TTM EPS | -0.03x | -15.62x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 38.69x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 11.14x |
| Price / BookPrice ÷ Book value/share | — | 3.68x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
XOMAP delivers a 20.1% return on equity — every $100 of shareholder capital generates $20 in annual profit, vs $-5 for CDT. On the Piotroski fundamental quality scale (0–9), XOMAP scores 4/9 vs CDT's 1/9, reflecting mixed financial health.
| Metric | CDTCDT Equity Inc. | XOMAPXOMA Corporation |
|---|---|---|
| ROE (TTM)Return on equity | -4.7% | +20.1% |
| ROA (TTM)Return on assets | -2.4% | +8.3% |
| ROICReturn on invested capital | — | -37.6% |
| ROCEReturn on capital employed | — | -19.4% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 4 |
| Debt / EquityFinancial leverage | — | 1.46x |
| Net DebtTotal debt minus cash | $7M | $18M |
| Cash & Equiv.Liquid assets | $554,000 | $102M |
| Total DebtShort + long-term debt | $7M | $119M |
| Interest CoverageEBIT ÷ Interest expense | -15.44x | 2.20x |
Total Returns (with DRIP)
A $10,000 investment in XOMAP five years ago would be worth $14,590 today (with dividends reinvested), compared to $0 for CDT. Over the past 12 months, XOMAP leads with a +8.7% total return vs CDT's -99.4%. The 3-year compound annual growth rate (CAGR) favors XOMAP at 8.9% vs CDT's -98.2% — a key indicator of consistent wealth creation.
| Metric | CDTCDT Equity Inc. | XOMAPXOMA Corporation |
|---|---|---|
| YTD ReturnYear-to-date | -50.8% | -3.0% |
| 1-Year ReturnPast 12 months | -99.4% | +8.7% |
| 3-Year ReturnCumulative with dividends | -100.0% | +29.1% |
| 5-Year ReturnCumulative with dividends | -100.0% | +45.9% |
| 10-Year ReturnCumulative with dividends | -100.0% | +50.5% |
| CAGR (3Y)Annualised 3-year return | -98.2% | +8.9% |
Risk & Volatility
XOMAP is the less volatile stock with a 0.13 beta — it tends to amplify market swings less than CDT's 0.34 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. XOMAP currently trades 85.9% from its 52-week high vs CDT's 0.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CDTCDT Equity Inc. | XOMAPXOMA Corporation |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.34x | 0.13x |
| 52-Week HighHighest price in past year | $168.00 | $30.00 |
| 52-Week LowLowest price in past year | $0.58 | $24.96 |
| % of 52W HighCurrent price vs 52-week peak | +0.4% | +85.9% |
| RSI (14)Momentum oscillator 0–100 | 27.2 | 38.3 |
| Avg Volume (50D)Average daily shares traded | 575K | 991 |
Analyst Outlook
XOMAP is the only dividend payer here at 1.81% yield — a key consideration for income-focused portfolios.
| Metric | CDTCDT Equity Inc. | XOMAPXOMA Corporation |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | 9 |
| Dividend YieldAnnual dividend ÷ price | — | +1.8% |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | $0.47 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 22 | Mar 26 | Change |
|---|---|---|---|
| CDT Equity Inc. (CDT) | 100 | 0 | -100.0% |
| XOMA Corporation (XOMAP) | 100 | 97.57 | -2.4% |
XOMA Corporation (XOMAP) returned +46% over 5 years vs CDT Equity Inc. (CDT)'s -100%. A $10,000 investment in XOMAP 5 years ago would be worth $14,590 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| CDT Equity Inc. (CDT) | $0.00 | $0.00 | — |
| XOMA Corporation (XOMAP) | $55M | $28M | -48.6% |
XOMA Corporation's revenue grew from $55M (2015) to $28M (2024) — a -7.1% CAGR.
Chart 3EPS Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| CDT Equity Inc. (CDT) | -1.01 | -20.53 | -1932.7% |
| XOMA Corporation (XOMAP) | -1.82 | -1.65 | +9.3% |
XOMA Corporation's EPS grew from $-1.82 (2015) to $-1.65 (2024).
Chart 4Free Cash Flow — 5 Years
CDT Equity Inc. generated $-10M FCF in 2024 (-352% vs 2021). XOMA Corporation generated $-14M FCF in 2024 (-260% vs 2021).
CDT vs XOMAP: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is CDT or XOMAP a better buy right now?
Analysts rate XOMA Corporation (XOMAP) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — CDT or XOMAP?
Over the past 5 years, XOMA Corporation (XOMAP) delivered a total return of +45.9%, compared to -100.0% for CDT Equity Inc. (CDT). A $10,000 investment in XOMAP five years ago would be worth approximately $15K today (assuming dividends reinvested). Over 10 years, the gap is even starker: XOMAP returned +50.5% versus CDT's -100.0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — CDT or XOMAP?
By beta (market sensitivity over 5 years), XOMA Corporation (XOMAP) is the lower-risk stock at 0.13β versus CDT Equity Inc.'s 0.34β — meaning CDT is approximately 158% more volatile than XOMAP relative to the S&P 500.
04Which has better profit margins — CDT or XOMAP?
CDT Equity Inc. (CDT) is the more profitable company, earning 0.0% net margin versus -48.5% for XOMA Corporation — meaning it keeps 0.0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CDT leads at 0.0% versus -140.3% for XOMAP. At the gross margin level — before operating expenses — XOMAP leads at 99.3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — CDT or XOMAP?
In this comparison, XOMAP (1.8% yield) pays a dividend. CDT does not pay a meaningful dividend and should not be held primarily for income.
06Is CDT or XOMAP better for a retirement portfolio?
For long-horizon retirement investors, XOMA Corporation (XOMAP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.13), 1.8% yield). Both have compounded well over 10 years (XOMAP: +50.5%, CDT: -100.0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between CDT and XOMAP?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. XOMAP pays a dividend while CDT does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.